Summary
AZQ, an alkylating agent with lipophilic characteristics allowing CNS penetration was studied in patients with primary CNS malignancies refractory to surgical and radiotherapeutic modalities. Responses were evaluated by three criteria: neurologic examination, performance status and CT scan of the brain. Improvement in all three parameters with stable or decreasing doses of decadron was required for a partial response. Thirty-six poor risk (prior chematherapy) patients with Grades III and IV astrocytomas were treated with 30 mg/m2. Three patients had a partial response (14, 17, 60 weeks duration). Two patients had mixed responses (worsening of one disease parameter with improvement in another), four had stable disease and one patient had improvement in neurologic parameters with a stable CT scan. Twenty-six patients had increasing disease. Fifteen good risk patients (no prior chemotherapy) with recurrent grades III and IV astrocytomas were treated at a dose of 40 mg/m2 intravenously every three weeks. There were no objective responses in this group of patients. Three patients with nonastrocytomas were treated and no responses observed. The drug was well tolerated. Myelosuppression in the form of leukopenia and thrombocytopenia was the major toxicity. Myelosuppression required dose reductions in eight patients and discontinuation of therapy due to repeated treatment delays in two patients. AZQ at doses of 30 and 40 mg/m2 given on an intermittent bolus schedule is inactive in patients with Grades III and IV recurrent astrocytoma.
Similar content being viewed by others
References
Driscoll JS, Hazard GF, Wood HB Jr, Goldin A: Structure Antitumor Activity Relationships Among Quinone Derivatives. Cancer Chemotherapy Reports Part 23 (2), April, 1974.
Bender JF, Grillo-Lopez AJ, Posada JG: Diaziquone (AZQ) Invest New Drugs 1: 71, 1982.
AZQ (NSC-182986) Preclinical Brochure, Investigational Drug Branch, NCI.
Taylor SA, Belt RJ, Haas C, Hoogstraten B, Stephens RL Phase I trial of carbamic acid (AZQ, NSC 182986). Proc Am Assoc Cancer Res 22: 389, 1981 (Abstract).
Schilsky RL, Kelley JA, Ihde DC, Howser DM, Cordes RS, Young RC: Phase I trial and pharmacokinetics of aziridinyl-benzoquinone (NSC 182986) in humans. Cancer Res 42: 1582–1586, 1982.
Maral J, Poisson M, Pertuiset B, Weil M, Jacquillat CL: Phase II Evaluation of aziridinylbenzoquinone (AZQ) in the treatment of malignant glioblastoma. Fourth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Dec 14-17, 1983. Abstract 84.
Feun LG, Savaraj N, Bedikan AY, Leavens M, Burgess MA, Lu K, Smith RG, Benjamin RS, Bodey GP: Phase II study of 2,5-diaziridinyl, 3,6-bis (carboethoxyamino)-1,4-benziquinone (AZQ, NSC 182986) in recurrent malignant gliomas. Proc Am Assoc Cancer Res 1: 151, 1982 (Abstract).
Eagan R: Phase II study of AZQ in brain tumors. Am J Clin Oncol Oct; 6 (5): 577–8, 1983.
Schold SC, Friedman HS, Bjornsson TD, Falletta JM: Treatment of Patients with Recurrent Primary Brain Tumors with AZQ. Neurology May 34 (5): 615–9, 1984.
Bachur NR, Collins JM, Kelley JA, VanEcho DA, Kaplan RS, Whitacre M: Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benziquinone, plasma and cerebrospinal fluid kinetics. Clin Pharmacol Ther May 31 (5): 650–655, 1982. Bibliography.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Taylor, S.A., McCracken, J.D., Eyre, H.J. et al. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group study. J Neuro-Oncol 3, 131–135 (1985). https://doi.org/10.1007/BF02228889
Issue Date:
DOI: https://doi.org/10.1007/BF02228889